New research published online in The FASEB Journal suggests that the suppression of thyroid hormone receptor activity locally in the retina protects cone photoreceptor cells in mouse models of human retinal degenerative diseases. Cone photoreceptor cells are located in the retina, in the back of the eye, and are responsible for light stimulation and sensation. Thyroid hormone inhibitors could be administered through topical medications or eyedrops.
"We wish to see the development of therapeutic agents or eyedrops targeting thyroid hormone locally in the retina to benefit patients with retinal degeneration, specifically by slowing cone cell death and prolonging the life span of cone cells in young and aged patient populations," said Xi-Qin Ding, Ph.D., a researcher involved in the work at the Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Scientists used two mouse models of human retinal degenerative diseases, Leber congenital amaurosis and achromatopsia, to test the effectiveness of thyroid hormone receptor inhibition. They treated animals with drugs that block the thyroid hormone receptor and evaluated cone cell survival and death in the drug-treated mice compared to controls (vehicle/placebo-treated mice). They also genetically deleted the thyroid hormone receptor in the two mouse models and evaluated cone cell survival and death in mice with and without thyroid hormone receptor deletion.
"The ubiquitous actions of thyroid hormone have long been known but continue to offer a panoply of new ideas, at many sites," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. "Here we have a promising lead on the ophthalmological axis."
Submit to The FASEB Journal by visiting http://fasebj.msubmit.net, and receive monthly highlights by signing up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the world's most cited biology journals and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.
FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
Details: Hongwei Ma, Fan Yang, Michael R. Butler, Joshua Belcher, T. Michael Redmond, Andrew T. Placzek, Thomas S. Scanlan, and Xi-Qin Ding. Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration. FASEB J. doi:10.1096/fj.201601166RR ; http://www.fasebj.org/content/early/2017/04/20/fj.201601166RR.abstract
Journal
The FASEB Journal